ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2571

Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis

Nisha Kwantra1, Marina Magrey2, Philip J. Mease3, Joachim Sieper4, Robert B.M. Landewé5, Xin Wang6, Apinya Lertratanakul1, Jaclyn K. Anderson1 and Nael Mostafa1, 1AbbVie Inc., North Chicago, IL, 2Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, 3Swedish Medical Center and University of Washington, Seattle, WA, 4University Clinic Benjamin Franklin, Berlin, Germany, 5Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 6AbbVie, North Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adalimumab, axial spondyloarthritis and remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:
In patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) in the ABILITY-3 study who achieved sustained remission with adalimumab (ADA), continued ADA therapy was associated with significantly fewer pts flaring than treatment withdrawal. Sustained remission is an important treatment goal in pts with nr-axSpA, but factors predicting sustained remission and absence of flare are unknown. The purpose of this analysis was to determine whether an ADA concentration threshold is predictive of achievement of sustained remission and absence of flare in pts with nr-axSpA.

Methods:
ABILITY-3 included a 28-wk open-label (OL) ADA (40 mg every other wk) lead-in in which pts who achieved sustained remission (ASDAS <1.3 at wks 16, 20, 24, and 28) were randomized to double-blind (DB) placebo (PBO) or continued ADA for 40 wks (68 wks total). Pts not achieving remission were discontinued at wks 20, 24, or 28. The primary efficacy variable was the proportion of pts who did not experience a flare (ASDAS ≥2.1 at 2 consecutive visits) by wk 68. Pts who flared received OL ADA rescue. ADA trough concentrations at wks 12 or 28 were used to predict achieving sustained remission by wk 28 (all OL patients, N=673) and absence of flare at wk 68 (patients randomized to DB ADA, n=152). Threshold analysis was conducted by constructing receiver operating characteristic (ROC) curves (R Ver 3.3.3) to assess predictive ADA trough concentration thresholds based on specificity and sensitivity values.

Results:
Of 673 pts enrolled in the OL phase, 305 met criteria for remission at wk 28 and were randomized to DB treatment. Mean ± SD ADA trough concentrations were 6.68±5.23 μg/mL at wk 12 and 8.36±5.27 μg/mL at wk 28. During the DB phase, 81 and 45 pts flared and 68 and 36 pts received ≥12 wks of OL ADA rescue in PBO (n=153) and ADA (n=152) arms, respectively. ADA mean ± SD trough concentration at wk 68 for pts randomized to DB ADA with flare (7.64±5.22 μg/mL) was slightly lower than for DB ADA pts without flare (8.12±4.35 μg/mL). ROC curves showed AUC values ≤0.6 for achieving sustained remission by wk 28 and absence of flare at wk 68, with no concentration threshold meeting sensitivity and specificity criteria for reliable prediction of such endpoints (Figure).

Conclusion:
ROC analyses did not identify an ADA trough concentration threshold that reliably predicted whether a pt with nr-axSpA would achieve sustained remission (by wk 28) or absence of flare (at wk 68).

Figure.  Receiver Operating Characteristic Curves to Predict Sustained Remission by Week 28 and Absence of Flare at Week 68 by Adalimumab Serum Concentration

 


Disclosure: N. Kwantra, AbbVie Inc., 1, 3; M. Magrey, Amgen, AbbVie, and UCB Pharma, 2,UCB and Janssen, 5; P. J. Mease, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB, 2,AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB, 5,AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer, and UCB, 8; J. Sieper, AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB, 5,AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB., 8; R. B. M. Landewé, Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Janssen (formerly Centocor), Galapagos, GlaxoSmithKline, Novartis, Novo-Nordisk, Merck, Pfizer, Roche, Schering-Plough, TiGenix, UCB, and Wyeth, 5, 9,Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, and Wyeth, 2,Abbott/AbbVie, Amgen, Bristol Myers Squibb, Janssen (formerly Centocor), Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth., 8; X. Wang, AbbVie Inc., 1, 3; A. Lertratanakul, AbbVie Inc., 1, 3; J. K. Anderson, AbbVie Inc., 1, 3; N. Mostafa, AbbVie Inc., 1, 3.

To cite this abstract in AMA style:

Kwantra N, Magrey M, Mease PJ, Sieper J, Landewé RBM, Wang X, Lertratanakul A, Anderson JK, Mostafa N. Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/adalimumab-serum-concentration-fails-to-predict-achievement-of-sustained-remission-or-absence-of-flare-for-patients-with-non-radiographic-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adalimumab-serum-concentration-fails-to-predict-achievement-of-sustained-remission-or-absence-of-flare-for-patients-with-non-radiographic-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology